Please assess the completion status of the following clinical trial:

Trial Title: Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females 30 years of age or older.~2. Subjects who have the clinical diagnosis of probable AD (30) ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR), cognitive normal elderly (30) age \>60 and cognitive normal young subjects (30) ages 30-60.~3. Normal subjects with Clinical Dementia Rating (CDR) 0-0.5 and AD subjects with CDR of 0.5 or greater.~Exclusion Criteria:~1. Subjects unable to lie down without moving for 30 minutes.~2. Women who are pregnant or who cannot stop breast feeding for 24 hours.~3. Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc,.~4. Subjects who are too claustrophobic to perform the tests.~5. Subject who have had previous brain irradiation, stroke or brain tumor(s)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Alzheimer's Disease (Type: EXPERIMENTAL): Subjects who have the clinical diagnosis of probable AD ages 50 and older who have a study partner who is the participant's power of attorney (POA) or legally authorized representative (LAR).~Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
- Cognitive Normal Elderly (Type: ACTIVE_COMPARATOR): Cognitive Normal subjects who are greater than 60 years of age. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.
- Cognitive Normal Young (Type: ACTIVE_COMPARATOR): Cognitively normal subjects who are between 30-60 years old. Interventions include C11 PiB PET/CT and F-18 Flutametamol PET/CT with C11 PiB PET/CT performed first.

Based on this trial design, predict the completion outcome and termination type (if applicable).